All In Biotech

Drug Trial Radar · NCT07762014

rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older

Randomized, Double-blind, Phase 2 Clinical Trial Controlled With Conventional Bacillus Calmette-Guérin (BCG) Vaccine to Evaluate the Safety and Immunogenicity of a Recombinant BCG Vaccine That Expresses the Respiratory Syncytial Virus (RSV) Nucleoprotein (N) (rBCG-N-RSV) in Adults Over 60 Years of Age.

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

Sep 7, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Biothervax SpAIndustry
Sponsor type
Industry
Collaborators
Pharmassist Ltd; Hellenic Pasteur Institute; Sotiria Thoracic Diseases Hospital of Athens
First posted
Aug 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cellular immune response against RSV nucleoprotein (N) generated by the rBCG-N-RSV vaccine in adults older than 60 years as compared to the response induced by the conventional BCG.

Conditions

  • Respiratory Syncytial Virus Infection Prevention
  • Tuberculosis Prevention

Interventions

  • Vaccination with rBCG-N-RSVBiological

    Intradermal vaccination with rBCG-N-RSV that expresses the N protein of the respiratory syncytial virus (RSV)

  • Vaccination with conventional BCG (BCG-WT)Biological

    Intradermal vaccination with conventional BCG (BCG-WT).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence, intensity, and duration of the local solicited AEs (evolution of the "flare-up") until the generation of the scarTime frame: From vaccination through 180 days post-vaccination
  2. Occurrence, intensity and duration of unsolicited AEs during the 6-month follow-up.Time frame: From vaccination through 180 days post-vaccination
  3. Occurrence of AEs during the 6-month follow-up duration.Time frame: From vaccination through 180 days post-vaccination
  4. Alterations to the hemogram and/or biochemical profile at 30- and 180- days post vaccination compared to pre-vaccination profileTime frame: Day 30 and day 180 post-vaccination
  5. Production of IFN-γ and IL-2 by T cells upon exposure to purified protein derivative (PPD) mycobacterial antigen via ELISPOT 7 days prior vaccination and 30- and 180-days post vaccination.Time frame: Day 30 and day 180 post-vaccination
  6. Production of IFN-γ and IL-2 by T cells upon exposure to recombinant RSV nucleoprotein antigen via ELISPOT 7 days prior vaccination and 30- and 180-days post vaccinationTime frame: Day 30 and day 180 post-vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sotiria Thoracic Diseases Hospital of Athens

    Athens, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.